Polish Treasury sources have indicated that it is hoped to complete theprivatization of two drug companies in the Polfa group - Polfa Krakow SA and Polfa Rzeszow SA - by the fall of this year. And by year-end, it is expected that Polpharma SA of Starogard Gdanski, PZF Polfa of Poznan and Polfa Tarchomin will also have been sold off to investors, with 15% of the equity left with the workforce and 5% with the government.
Only two Polish drugmakers have so far moved towards privatization: the Kutno-based Polfa plant, which belongs 49% to the USA Enterprise Investors fund and to Polish institutions, with the balance held by small investors; and Jelfa SA, in which small investors also have a 40% stake, though the state retains 60% of this firm.
Polish Market Tripled Since 1989 Polish drug market volume has tripled since 1989 to about $1.5 billion, with drug spending estimated at some $40 per head of population a year. Some foreign drug company sources suggest that current market volume calculated in terms of economic drug prices is around $2-$2.5 billion and argue that if prices were to be liberalized the domestic market has a potential to increase to $3.5-$4 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze